Surfactant Utilization Evaluation in a Major Teaching Hospital in West of Iran: An Observational, Prospective Study
Background: The respiratory distress syndrome (RDS) is a common pulmonary disorder that usually occurs as a result of preterm labor and is associated with lack of surfactant. The aim of this study was to evaluate the pattern of surfactant prescription in Alzahra teaching hospital in Tabriz, Iran. Methods: This drug use evaluation (DUE) study was conducted in the neonatal intensive care unit (NICU) of Al-Zahra Hospital, Tabriz, Iran. The demographic and clinical data collection was performed using clinical records of patients. The pattern of surfactant replacement therapy was evaluated and compared with the European Consensus Guideline on the management of respiratory distress syndrome in 2016. Results: A total of 252 premature infants who received surfactant between August 2017 and March 2018 were included. 80.8% of neonates were born by cesarean section. The most used surfactant was Curosurf®, which was used in 82.1% of cases. Only 34.9% of the infants received within 8 hours of birth. Moreover, 79% of infants received the standard dose of surfactant, while 9.5 % and 11.5% were given high and low doses of surfactant, respectively. Conclusion: The pattern of surfactant replacement therapy was not completely according to the guidelines, particularly regarding the time of administration. Considering the importance of dose and timely administration of surfactant, providing strategies to decrease these errors are important.
2. Gharib M. J, Dormanesh B, Aminian A, Kosari K, Assadi S. A Model for Analyzing the Results of Surfactant Administration in Neonatal Wards. Biomed Pharmacol J 2016;9(1).
3. Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007;196(2):147.e1-8.
4. Ainsworth SB, Milligan DW. Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review. Am J Respir Med 2002;1(6):417-33.
5. Banerjee S, Fernandez R, Fox GF, et al. Surfactant replacement therapy for respiratory distress syndrome in preterm infants: United Kingdom national consensus. Pediatr Res 2019; 86:12.
6. Baroutis G, Kaleyias J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr 2003;162(7-8):476-480.
7. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; North American Study Group. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004;21(3):109-19.
8. Martin JA, Hamilton BE, Osterman MJK. Births in the United States, 2018. NCHS Data Brief 2019;(346):1-8.
9. Karnati S, Kollikonda S, Abu-Shaweesh J. Late preterm infants - Changing trends and continuing challenges. Int J Pediatr Adolesc Med 2020;7(1):36-44.
10. Sweet DG, Carnielli V, Greisen G, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update. Neonatology 2017;111(2):107-125.
11. Challis P, Nydert P, Håkansson S, Norman M. Association of Adherence to Surfactant Best Practice Uses With Clinical Outcomes Among Neonates in Sweden. JAMA Netw Open 2021;4(5):e217269.
12. Sweet DG, Carnielli V, Greisen G, et al. . European Consensus Guidelines on the Management of Respiratory Distress Syndrome 2019 update. Neonatology 2019;115(4):432-450.
13. Graziosi G, Bakker C, Brouwers H, Bruinse H . Elective cesarean section is preferred after the completion of a minimum of 38 weeks of pregnancy, Ned Tijdschr Geneeskd 1999;143(1):60.
14. Dargaville P. A, Gerber A, Johansson S, et al. Incidence and outcome of CPAP failure in preterm infants. Pediatrics 2016;138(1):e20153985.
15. Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks' gestation. Pediatrics 2004; 113(6):e560-3.
16. Speer CP, Gefeller O, Groneck P, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 1995;72(1):F8-F13.
17. Proquitté H, Dushe T, Hammer H, Rüdiger M, Schmalisch G, Wauer RR. Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants. Respir Med 2007;101(1):169-76.
18. Lam BC, Ng YK, Wong KY. Randomized trial comparing two natural surfactants (Survanta vs. bLES) for treatment of neonatal respiratory distress syndrome. Pediatr Pulmonol 2005;39(1):64-9.
19. Lemyre B, Fusch C, Schmölzer GM, et al. Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial. PLoS One 2017;12(5):e0175922.
20. Clark RH, Auten RL, Peabody J. A comparison of the outcomes of neonates treated with two different natural surfactants. J Pediatr 2001;139(6):828-31.
21. Khiali S, Eskandari S, Hamishehkar H, Maroufi P, Rezaee H. Vancomycin Utilization Evaluation in a Major Teaching Hospital in West of Iran. J Pharm Care 2020;8(2): 70-74.
22. Safaie N, Azizi H, Khiali S, Entezari-Maleki T. The impact of clinical pharmacist interventions on medication errors management in the postoperative cardiac intensive care unit. Pharm Sci 2021;27(3):433-438.
23. Khalili H, Karimzadeh I, Mirzabeigi P, Dashti-Khavidaki S. Evaluation of clinical pharmacist's interventions in an infectious diseases ward and impact on patient's direct medication cost. Eur J Intern Med 2013;24(3):227-33.
|Issue||Vol 9, No 4 (Autumn 2021)|
|Preterm Infants Respiratory Distress Syndrome Surfactant|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|